Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02597049 · ClinicalTrials.gov registry record · Phase 3
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT02597049 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 424 participants.
The verdict
NCT02597049, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG SGLT2 inhibitor
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02597049
The ClinicalTrials.gov registry entry for NCT02597049 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02597049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02597049 about?
NCT02597049 is a clinical study titled "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus". The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
What is the current status of trial NCT02597049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2015-11. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02597049?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), SGLT2 inhibitor (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT02597049?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.